corecubed, a full-service marketing and sales consulting firm specializing in the home care sector, has been honored with five 2023 Aster Awards, including four gold and one silver award.
ASHEVILLE, N.C., Oct. 19, 2023 /PRNewswire-PRWeb/ — corecubed, a full-service marketing and sales consulting firm specializing in the home care sector, has been honored with five 2023 Aster Awards, including four gold and one silver award.
The Aster Awards is one of the largest and most respected national/international competitions of its kind. This elite program has recognized outstanding healthcare professionals for excellence in their advertising/marketing efforts for over 20 years.
The 2023 Aster Awards received entries from across the entire United States and abroad. All entries are reviewed by a panel of industry experts and are scored on multiple criteria with a possibility of 100 percent. Participants’ entries compete against similar-sized organizations in their specific groups and categories.
Awards were issued for entries that received top marks from judges, placing them in the top 16% of the nation for advertising excellence. Judging criteria included creativity, layout and design, functionality, message effectiveness, production quality, and overall appeal and execution.
Gold Awards – Score of 95% to 99% (top 5% in the nation)
Silver Awards – Score of 90% to 94% (top 12% in the nation)
“I am so proud of the corecubed team for earning these prestigious advertising awards for our clients. We are dedicated to producing high-quality marketing results for our care companies. It’s an honor to achieve this distinction,” said Marissa Snook, President and CEO of corecubed.
“Many agencies and organizations offered incredibly informative and creative communications. Our hats off to everyone for amazing entries,” said Melinda Lucas, Aster Awards Program Coordinator.
corecubed is a full-service home care marketing and sales consulting firm specializing in helping aging care service businesses and home care agencies grow with innovative, industry-specific, integrated marketing strategies and solutions. Our team members are located around the United States and have extensive experience in home care, home health, and aging care operations and marketing. Further information can be found at www.corecubed.com, on Facebook, LinkedIn, or by calling 800-370-6580.
Developed in close collaboration with leading biopharma partners, Genedata Expressionist evolves with each release to meet the latest industry requirements, enabling out-of-the-box implementation of custom solutions. Genedata Expressionist 17.5 goes further by introducing an extended API that takes customization to a new level. Biopharma organizations can now seamlessly integrate bespoke software functionalities into Genedata Expressionist, enabling internal experts—or Genedata professional services—to leverage their domain knowledge and programming skills to deliver data processing, analysis, and reporting workflows that meet unique business needs.
“To maximize efficiencies in today’s data-driven drug development processes, automation must extend across entire analytical workflows, including traditional process bottlenecks such as expert review” stated Othmar Pfannes, Ph.D., CEO of Genedata. “By simplifying and accelerating data review and offering unmatched data processing flexibility, this release solidifies the position of Genedata Expressionist as the industry front-runner for streamlining and automating MS-based analytical workflows and provides biopharma organizations with faster, more accurate, and more efficient ways of working.”
About Genedata Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo. http://www.genedata.com LinkedIn https://www.linkedin.com/company/genedata/ Twitter https://twitter.com/Genedata YouTube https://www.youtube.com/GenedataSoftware
Disclaimer The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
This year, four distinguished individuals from Boston IVF were recognized nationally by the ASRM for their exceptional contributions:
Yuval Fouks, MD, PhD, MPH a dedicated Research Fellow at Boston IVF, was honored with the ASRM 2023 IN TRAINING AWARD FOR RESEARCH for his noteworthy publication in Fertility and Sterility. His paper, titled “The Impact of Fertility Treatments on Embryo Aneuploidy and Live Birthrates in Comparison to Patients with Normal Ovarian Reserve,” sheds light on the absence of significant impacts on embryo aneuploidy or live birth rates in patients with normal ovarian reserve. (Source: Fertility & Sterility)
Quetrell Heyward, MD, MBA, a Reproductive Endocrinology and Infertility Fellow at Boston IVF & Beth Israel Deaconess Medical Center, received the prestigious ASRM 2023 INVESTIGATOR ACHIEVEMENT AWARD. This recognition was bestowed in acknowledgment of his insightful abstract titled “Intrauterine Insemination (IUI): More Is Not Always Better,” which highlights the nuances and considerations surrounding the effectiveness of IUI treatment.
Kim Thornton, MD, and Alan Penzias, MD, renowned reproductive endocrinologists at Boston IVF, were acknowledged during EMD Serono’s Diversity, Equity, and Inclusion Fellowship Awards Recognition Ceremony as I’M IN R.E.I. DIVERSITY FELLOWSHIP GRANT MENTORS. This recognition is a testament to their unwavering commitment to fostering diversity and inclusion within the field.
The roots of Boston IVF’s prolific research program run deep, in collaboration with Harvard Medical School, the Beth Israel Deaconess Medical Center, and other prestigious clinical affiliates. Since its inception, Boston IVF has contributed more than 500 papers and abstracts to the field, many of which have translated into life-changing innovations for individuals seeking successful pregnancies and family-building opportunities.
In 2019, Boston IVF expanded its global impact through a partnership with the renowned, Spain-based Eugin Group, broadening the scope of research possibilities and initiatives.
Led by Boston IVF’s Chief Scientific Officer, Denny Sakkas, PhD and Director of Clinical Research and board-certified reproductive endocrinologist, Denis Vaughan, MD, Boston IVF’s in-house, full-time research program consists of over 50 experts, including reproductive endocrinologists, scientists, embryologists, clinicians, data analysts, and more. Together, they play a pivotal role in advancing the field of reproductive science and introducing new clinical protocols, surgical techniques, public policy analyses, and other valuable insights to their peers worldwide.
“Through our dedicated research department, we strive daily to unravel the mysteries of fertility, unlocking the potential for hope and fulfillment for countless individuals and couples,” said Denis Vaughan, MD.
Denny Sakkas, PhD, also added, “Every discovery, every breakthrough, is a testament to our commitment to transforming dreams into reality.”
For over three decades, Boston IVF’s innovative research has yielded remarkable breakthroughs in fertility care, including several notable milestones:
David Stern, CEO of Boston IVF, expressed his enthusiasm for the 2023 ASRM Congress, noting, “We take pride in our many distinguished experts who presented at this exciting exposition. It reflects our ongoing commitment to advancing fertility treatment options and improving the lives of our patients. We are grateful for every opportunity to share our knowledge and collaborate with fellow experts in the field.”
Highlighted Boston IVF Presenters and Topics at the 2023 ASRM Congress:
Alan Penzias, MD: “ART Access for All: A Value-Based Analysis”
Ann Korkidakis, MD: “Racial and Ethnic Determinants of Access to Infertility Care in a State with a Comprehensive Infertility Mandate”
Quetrell Hayward, MD, MBA: “Intrauterine Insemination (IUI): More is not Always Better” and “Reproductive Outcomes of IVF Following a Large-Scale Merger: Is Bigger Always Better?”
Riwa Sabbagh, MD: “Using In Situ Gene Expression to Create a Three-Dimensional Map of Human Blastocysts” and “Lower Live Birth Rates with Increasing Maternal Age in Donor Oocyte Cycles”
Boston IVF is one of the largest and most experienced fertility networks in the United States, with more than 150,000 babies born since 1986. Founded as one of the nation’s first private practice IVF centers, the Boston IVF network has grown to include over 30 reproductive endocrinologists across 30 centers throughout Massachusetts, Maine, New Hampshire, Rhode Island, New York, Delaware, Idaho, Indiana, North Carolina, Ohio, and Utah. A renowned innovator of reproductive technologies, advanced protocols, and cutting-edge research, Boston IVF has achieved numerous “firsts” in reproductive care. Its scientific and research arm continues to pave the way for breakthroughs in fertility care and its accredited REI Fellowship Program has graduated numerous reproductive endocrinologists as part of its mission to train the next generation of fertility experts.
Transaction Enhances OCP’s Expertise in Sports Medicine and Expands Its Presence in Missouri FORT LAUDERDALE, Fla., Oct. 19, 2023 /PRNewswire/ — Orthopedic Care Partners (OCP), an orthopedic practice management platform comprised of The Orthopaedic Institute, The Steadman Clinic, Motion…
Featuring 65% Off + Free Shipping on Robern Vanities, Linen Cabinets, and Lighted, Decorative Mirrors
BRISTOL, Pa., Oct. 18, 2023 /PRNewswire-PRWeb/ — Robern, a leading designer and manufacturer of vanities, medicine cabinets, mirrors, and lighting, is reducing inventory of select designs from some of its best-selling collections. The Robern Warehouse Sales on-line event is slated to run from October 9 to November 9, 2023. This limited time event on select pieces feature sophisticated designs from Robern’s highly lauded Craft Series of bathroom furnishings, its Vitality Lighted Mirrors collection, and versatile Craft Series Mirrors that include an eclectic mix of materials and frame styles.
The Robern designs are available for purchase at 65 percent off list and can be viewed at https://sale.robern.com. All sales include free shipping. Due to the nature of the warehouse sale, all sales are final and Robern cannot accept any returns or exchanges.
About ROBERN At Robern, the bathroom is our favorite room. It is our private space. It is our sanctuary. For more than 50 years, Robern has specialized in creating luxurious spaces with a powerful product portfolio that moves beyond the expected industry standard to transform rooms into interiors of impeccable elegance. By taking a more holistic approach to the bathroom and its importance, not only aesthetically, but to overall health and wellbeing, Robern has become a driving force within residential and commercial design with an artful blend of sophisticated form, innovative technology, impeccable craftsmanship, and quality materials.
Founded in 1968 in Bristol, Penn. by Rosa and Bernie Meyers, Robern’s mission remains grounded in the Meyers’ belief that individual style should be celebrated and fostered. Today, their pioneering approach, commitment to craftsmanship, quality, attention to detail, and utilization of the finest materials available, remains foundational to the Robern brand and is evident in every piece still hand-assembled on-site at its Bristol headquarters today.
In 1995, Robern joined the Kohler Co. family of businesses, building upon the breadth and depth of the brand’s comprehensive and thoughtful approach to creating exceptional styling spaces. From its humble beginnings to a technological force within home design, Robern has become a leading choice for designers, architects, and consumers seeking out the finest in vanities, medicine cabinets, mirrors, and lighting. For additional information on Robern products, customers may call 1 (800) 877-2376 or visit http://www.robern.com.
About Kohler Co. For 150 years, Kohler Co. has been a global leader in design and innovation, dedicated to providing gracious living through kitchen and bath products; luxury cabinetry, tile and lighting; distributed energy solutions – home energy, industrial power systems, and powertrain technologies – and luxury hospitality experiences and major championship golf. Kohler’s Whistling Straits golf course hosted the 43rd Ryder Cup in 2021. Privately held Kohler Co. was founded in 1873 and is headquartered in Kohler, Wisconsin. The company also develops solutions to address pressing issues, such as clean water and sanitation, for underserved communities around the world to enhance the quality of life for current and future generations. KOHLERKitchen & Bath, Energy, Golf + Resort Destinations
What is an FSA and an HSA? These tax-advantaged accounts allow users to set aside pre-tax income to pay for eligible healthcare and everyday wellness expenses (as determined by the Internal Revenue Service). Contributions reduce the account holder’s taxable income and withdrawals are not taxed, if funds are used for qualified expenses.
How do I enroll? An FSA can only be opened through an employer during the benefits enrollment period or if there is a qualifying event to allow a mid-year election. Any money contributed to the FSA remains with the employer in the event that an employee leaves their job for any reason (with the exception of any COBRA extension, if applicable). An HSA, on the other hand, can be opened at any time either through an employer’s benefit program or individually through an HSA administrator, as long as the person or family covered by the account is enrolled in a qualified high-deductible health plan (HDHP). An HSA is an employee-owned account that always belongs to the individual and the money in the account accrues tax-free over time and can be used to pay for qualified expenses in retirement.
What are the contribution limits? Both employees and employers can contribute to an FSA or an HSA. Employee FSA contributions are made with pre-tax payroll contributions, but employers can also make post-tax contributions to the employee FSA. The total FSA contribution amount for the year is available from day one. HSA contributions are also considered tax free, but they can be made via automatic payroll contributions or via post-tax contributions throughout the year that can be taken as an above-the-line deduction at tax time. For 2024, HSA contribution maximums will increase to an all-time high of $4,150 for individual coverage in a qualified HDHP, and $8,300 for two-person or family coverage. The total amount of employer and employee contributions cannot surpass this amount. While 2024 FSA limits have not yet been announced, Mercer is predicting a more than 5% increase to $3,200.
Is there a spending deadline? An FSA has an annual spending deadline or a time by which the balance must be spent or remaining funds are lost. This is called a forfeiture. For most people, the FSA deadline is Dec. 31 each year; however, this deadline can vary based on an organization’s plan year. An employer may also offer an FSA deadline extension, such as a partial rollover of unused funds, a grace period (2.5 months after your plan year end date; typically March 15), and/or a run-out period. To help account holders avoid potential FSA forfeitures, FSA Store offers free FSA Deadline Alerts that remind consumers when their personal deadline is approaching. This helps to ensure they won’t lose FSA funds.
How can FSA and HSA funds be used? The list of qualified expenses for FSAs and HSAs goes well beyond doctor visits and copays. Thanks in part to advocacy efforts from Health-E Commerce and other industry leaders, eligibility has continued to expand to include everyday items like over-the-counter medications, contacts and eyeglasses, hearing aids, menstrual care products, drug-free pain relief, and even high-tech health monitoring and diagnostic devices. It’s important to review a comprehensive FSA and HSA eligibility list to understand how these tax-free funds can be used in conjunction with health plan coverage to maximize the health, wellness, and financial wellbeing for individuals and families throughout the coming year.
How much can I save? Both FSAs and HSAs can help users save an estimated 30% (or $30 on every $100) on eligible healthcare expenses, depending on an individual’s tax bracket. A key differentiator is that HSAs allow users to invest a portion of those contributions into stocks, bonds, and mutual funds for retirement. HSAs also offer a unique triple tax advantage — contributions are tax-free (either through payroll deduction or as an above-the-line deduction at tax time), interest grows tax-free, and distributions for qualified healthcare expenses are also tax-free. To help individuals plan their contributions and estimate their savings potential, Health-E Commerce offers a free FSA calculator, along with HSA calculators that illustrate tax savings potential and future value of the account. Consumers who are considering an HSA for next year, can use the free HSA My Way tool at HSA Store to explore the different ways an HSA can be used to support their lifestyle and wellness needs.
For additional information and tools, visit the HSA Store or FSA Store Learning Centers.
About Health-E Commerce Health-E Commerce is the parent brand to FSA Store, HSA Store and WellDeservedHealth, a family of online stores that serve the 70+ million consumers enrolled in pre-tax health and wellness accounts. The company also created Caring Mill, a popular private-label line of health products that benefits Children’s Health Fund and enables customers to make a donation with each purchase. Since 2010, the Health-E Commerce brands have led the direct-to-consumer e-commerce market for exclusively pre-tax health and wellness benefits. Health-E Commerce plays an essential role in expanding product eligibility for important new categories within the list of eligible medical expenses.
Plain language summaries, a regulatory requirement elsewhere in the world, are meant to provide the public with the results of a clinical trial in a way that is more easily understood (i.e., 6th-8th grade reading level). While still voluntary in the United States, there has been increased public outcry for transparency in the pharmaceutical industry and these plain language summary documents are required in the European Union (EU) under the EU Clinical Trial Regulation No. 536/2014.
This comes at a time when just 12 percent of Americans are considered proficient in their health literacy, according to the National Assessment of Adult Literacy, and most recent research out of the NIH shows that only about 14 percent of plain language summaries are available to clinical trial participants.
How does this help patient engagement?
“These health literacy numbers need to improve, and one way forward is to share information in formats that are accessible. AI-led technology like TrialAssure LINK will help the medical community, including researchers in biopharma, to more clearly communicate with participants and their families as to the results of the clinical trials and also increase treatment options. This initiative recognizes the importance of our collaboration, especially during Health Literacy Month this October,” said Prasad M. Koppolu, Chief Operating Officer, TrialAssure.
Koppolu continued, “By using TrialResults.com, we have charged past the lack of a current mandate for reporting these plain language summary documents and taken a step forward, posting understandable clinical trial results to help improve health literacy and give the entire pharmaceutical industry an opportunity to be more transparent.”
Plain language summaries help patients, their families, and the public at large by:
providing a better understanding of the clinical study that occurred,
giving more context and details around what the individual studies accomplished, or didn’t accomplish, and
helping them understand the value of personal contributions to science and empowering clinical trial participants to continue to be involved in clinical trials in the future.
On the TrialResults.com website, the public can learn about specific clinical trials for diseases or conditions of interest. Reading one of the approximately 50,000 plain language summaries available provides a starting point to understand the clinical trial at a high level – just enter a disease, condition, or study number in the search bar. The study sponsor will always be listed in the summary, making it easy for individuals to find direct and additional information on the sponsor website.
The plain language summary documents will be released on TrialResults.com in the following five groupings by condition and/or disease:
Oncology (available now)
Metabolic
Mental Health and Neurological
Respiratory
All others
To be notified when additional summaries are posted, email [email protected] to be added to the mailing list.
Reviewing the ClinicalTrials.gov record for further supporting data and understanding is recommended and a link will be available on TrialResults.com for each record. It should be emphasized that a physician should be consulted before making any healthcare decisions.
Saving one million hours by using AI to create 50,000 plain language summaries
“Three factors are converging in 2023 – the rise of public-facing generative AI technology, a resurgence in transparency initiatives with global health authorities, and mounting concerns related to health literacy despite major technological and scientific advances in recent decades,” said Zach Weingarden, Director of Product Solutions, TrialAssure.
Weingarden continues, “Plain language summary documents are notoriously time-consuming and can be challenging to write, and many pharmaceutical companies struggle to juggle resources between this and writing the required clinical study reports, completing other disclosure requirements, and filing their new drug applications. AI has the potential to turbocharge the initial drafting of these documents, automatically and in bulk, saving the skilled reviewers’ effort for a quick confirmation and finalization step. We have demonstrated this is possible by creating fully written drafts based solely upon data already available in public records.”
When manually drafting a plain language summary in the pharmaceutical industry, it takes approximately 20 hours per document to write from scratch. If this estimate is accurate, to draft 50,000 plain language summary documents would take approximately 1,000,000 hours. TrialAssure was able to reduce this workload to less than one day. Time, effort and cost no longer remain an excuse for transparency.
Accuracy of AI-generated plain language summary documents
“We hope this exercise will show that these AI-generated drafts are a great start, but AI has limited abilities and the use of AI is not a complete replacement of a skilled human writer,” said Weingarden. “Furthermore, we are limited to the data that is available in the ClinicalTrials.gov record. Depending on the structure and format of the data, it may be difficult for the AI to interpret and summarize accurately. We expect this to be an insightful demonstration of a committed path forward towards transparency, harvesting the scalable power and working to improve the limitations of our AI technology and welcome feedback from the scientific community.”
Feedback on the plain language summaries posted to TrialResults.com and generated by TrialAssure’s LINK application can be emailed to [email protected] and will help improve the quality of the plain language summaries.
With industry feedback incorporated and further Sponsor collaboration, TrialAssure will look to implement a new process in the near future that will use AI to automatically generate a plain language summary whenever a new record is available. This will scan ClinicalTrials.gov data daily, allowing new plain language summary documents to be available on TrialResults.com in near real-time.
TrialAssure, Inc. is a leading, global clinical trial disclosure and data transparency provider with unmatched experience in helping navigate complex regulatory compliance challenges. TrialAssure provides fast, affordable, and intelligent software and service solutions to facilitate clinical trial disclosure (registration and results reporting), document and data anonymization, and enhanced patient engagement, while delivering the highest quality clinical trial transparency deliverables that exceed the most stringent requirements. Established in 2009, TrialAssure regularly adapts to ever-changing clinical trial disclosure and data transparency requirements and was named Data Solution of the Year – Healthcare in the Data Breakthrough Awards.
Nanovis celebrates this significant milestone as it continues to commercialize nanotechnology and improve patient outcomes.
COLUMBIA CITY, Ind., Oct. 17, 2023 /PRNewswire-PRWeb/ — Nanovis, a pioneer in nanotechnology solutions, is thrilled to announce the successful completion of its 500th surgery using the groundbreaking FortiFix™ pedicle screws. This milestone is not just a numeric achievement but a testament to the innovative application of FDA-designated nanotechnology, ensuring enhanced patient recovery and surgical success.
FortiFix™ pedicle screws, distinguished as the first FDA-cleared pedicle screw with a nanotechnology designation, have demonstrated a remarkable track record in facilitating biologic fixation that increases and accelerates bone-to-implant interface for osseointegration. Over 3,000 pedicle screws have been implanted in the initial 500 surgeries, with patients experiencing positive outcomes, including no known infections or non-fusions noted in the Maude database. The system has proven its efficacy across a spectrum of surgeries, including degenerative, deformity, trauma, and revision surgeries.
Dr. Todd Bonvallet, from Atlanta, GA, shares his experience: “To address the risk of pseudoarthrosis, or the failure of bone fusion to occur as intended, I have incorporated Nanovis’ nanotechnology implants to support rapid bone growth on and through the fusion construct. Utilizing Nanovis nanotechnology pedicle screws (nano FortiFix™) over the last 18 months has yielded impressive results, promoting rapid osseointegration and leading to faster and more complete fusion.”
Nanovis’ commitment to advancing spinal surgery with nanotechnology is further echoed by surgeon Dr. Wade Ceola, from Glenwood Springs, CO, who has witnessed firsthand the positive impact of nano FortiCore™ interbodies in the cervical spine over several years, and now, nano FortiFix™ pedicle screws in the lumbar spine. “The early bone ongrowth observed with the use of FortiFix™ pedicle screws not only improves healing but also ensures stronger fixation, enhancing the overall stability and success of spinal surgeries.”
“Our vision is to Enable and Engage – Enable innovation that will Engage health care and patients. With over a decade of research, we have demonstrated the biological advantages of our nanoVIS Ti Surface Technology™. Since 2019, we have had 7 spinal devices cleared by the FDA with a nanotechnology designation, including the first ever PEEK Titanium Hybrid Interbodies (nano FortiCore™) and the first ever Open and MIS pedicle screw systems (nano FortiFix™). Since the clearance of our nano FortiFix™ pedicle screw systems, I am astounded by the positive feedback we get from surgeons on their experience with the product and how the nanotechnology is helping patients heal,” states Nanovis CEO, Brian More.
More continued with his statement saying, “Medtronic’s implementation of nanotechnology, as evidenced in their recent clearance of their nanoLOCK™ surface technology on pedicle screws, validates our position that nanotechnology is clinically advancing beyond the interbody space. In this rapidly changing world of device surface technology, we should not be satisfied with traditionally manufactured implants when our nanoVIS Ti Surface Technology™ solution is truly making a difference in the lives of patients.”
Nanovis will be showcasing the nano FortiFix™ pedicle screws at the NASS 38th Annual Meeting in Los Angeles, CA, at Booth #1111 from October 18-21, 2023.
To read more about Dr. Bonvallet’s experiences with nanoVIS Ti Surface Technology™, click here.
To read more about Dr. Ceola’s experiences with nanoVIS Ti Surface Technology™, click here.
Ready to learn more about the science behind nanoVIS Ti Surface Technology™? Join us on LinkedIn.
About Nanovis
Nanovis is a technology-driven company committed to discovering unmet clinical needs, developing innovative and enabling solutions, and validating new technologies for clinical and market acceptance. The company, through its subsidiary Nanovis Spine, has successfully commercialized its proprietary nanoVIS Ti Surface Technology™ across a range of spinal implants, including the nano FortiFix™ Pedicle Screws and Nano FortiCore™ PEEK Titanium Hybrid Interbodies, the latter being enriched with OsteoSync™ technology licensed from Sites Medical.
Notably, the nanoVIS Ti Surface Technology™ platform is showing potential in pre-clinical studies to evolve into an antimicrobial surface in select markets, while concurrently, Nanovis is innovating a next-generation antimicrobial technology aimed at combating localized infections across various applications, including skin, transcutaneous devices, and orthopedic implants.
NEW YORK, Oct. 17, 2023 /PRNewswire/ — SilverAssist, a leading provider of senior care resources and solutions, announces the launch of an integrated solution aimed at simplifying the journey to finding the right senior care. With the recent acquisition of Oasis Senior Advisors, a…
Partnership to improve access to high-quality medical device that’s essential for safe surgery and currently absent outside of wealthy countries NAIROBI, Kenya and NEW YORK, Oct. 16, 2023 /PRNewswire/ — Ahead of World Anesthesia Day, the world’s largest cleft organization, Smile Train,…
